Sat, 20 Aug 2022

NEW YORK, NY / ACCESSWIRE / August 2, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Missfresh Limited (NASDAQ:MF)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/mf-class-action-missfresh-limited-submission-form?prid=30498&wire=1
Lead Plaintiff Deadline: September 12, 2022
This lawsuit is on behalf of persons who purchased or otherwise acquired Missfresh securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Missfresh's June 2021 initial public offering.

Allegations against MF include that: (1) Missfresh provided false financial figures in its registration statement
and related prospectus issued in connection with the Company's June 2021 initial public offering; (2) Missfresh would need to amend its financial figures; (3) Missfresh, among other things, had lesser net revenues for the quarter ended March 31, 2021; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.

TG Therapeutics, Inc. (NASDAQ:TGTX)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/tgtx-lawsuit-loss-submission-form?prid=30498&wire=1
Lead Plaintiff Deadline: September 16, 2022
Class Period: January 15, 2020 - May 31, 2022

Allegations against TGTX include that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

Enochian BioSciences, Inc. (NASDAQ:ENOB)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/enochian-biosciences-inc-loss-submission-form?prid=30498&wire=1
Lead Plaintiff Deadline: September 26, 2022
Class Period: January 17, 2018 - June 27, 2022

Allegations against ENOB include that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

The Law Offices of Vincent Wong, Tuesday, August 2, 2022, Press release picture

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/710609/SHAREHOLDER-ALERT-MF-TGTX-ENOB-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

Sign up for Connecticut State News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!